Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A

Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A

SSSE:603139
26.36
CNY
-0.81
(-2.98%)
-1.81EPS
3.64BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A carries a market capitalization of 3.64B, placing it among publicly traded companies globally. Its enterprise value stands at 4.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.64B
Enterprise Value4.46B

Share Statistics

As of September 30, 2026, Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A has 106.45M shares outstanding.

Shares Outstanding106.45M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 6.66, and the price-to-book ratio stands at 5.41.

PS Ratio6.66
PB Ratio5.41
P/TBV Ratio6.27

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 8.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.46B versus a market cap of 3.64B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales8.58

Financial Position

As of September 30, 2026, Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A maintains a current ratio of 0.48, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 115.52, indicating elevated leverage, while an interest coverage ratio of -5.65 demonstrates limited ability to service its debt obligations.

Current Ratio0.48
Quick Ratio0.08
Debt / Equity115.52
Debt / EBITDA-4.62
Interest Coverage-5.65

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A posted a negative return on equity (ROE) of -26.79, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -8.69, reflecting losses generated across the asset base. The company generates approximately 646,922.88 in revenue per employee across its workforce of 804.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.65 indicates how many times Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-26.79
Return on Assets (ROA)-8.69
Revenue Per Employee646,922.88
Employee Count804.00
Inventory Turnover1.65

Taxes

CNY

Over the twelve months ended September 30, 2026, Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A recorded an income tax benefit of -4.08M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -187.65M and -199.51M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-4.08M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A's stock has gained approximately 9.29% over the past 52 weeks. The 50-day moving average sits at 33.79, while the 200-day moving average is 33.08.

52-Week Price Change9.29%
50-Day Moving Average33.79
200-Day Moving Average33.08

Income Statement

CNY

Over the twelve months ended September 30, 2026, Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A generated 520.13M in revenue and converted that into -199.51M in net income, yielding earnings per share of -1.81. EBITDA reached -188.11M, while operating income came in at -40.70M.

Revenue520.13M
Gross Profit167.59M
Operating Income-40.70M
Pretax Income-187.65M
Net Income-199.51M
EBITDA-188.11M
EBIT-188.11M
Earnings Per Share (EPS)-1.81

Balance Sheet

CNY

As of September 30, 2026, Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A holds 127.35M in cash and equivalents against 869.63M in total debt, resulting in a net debt position of 198.13M. Total book value stands at 672.54M, with working capital of -819.85M providing operational flexibility.

Cash & Cash Equivalents127.35M
Total Debt869.63M
Net Debt198.13M
Equity (Book Value)672.54M
Book Value Per Share6.32
Working Capital-819.85M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-467.81M

Margins

Over the twelve months ended September 30, 2026, Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A posted a gross margin of 32.22, reflecting its pricing power and cost economics. The operating margin of -7.83 and net profit margin of -38.36 provide insight into operational efficiency.

Gross Margin32.22
Operating Margin-7.83
Pretax Margin-36.08
Profit Margin-38.36
EBITDA Margin-36.17

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A paid dividends of 0.23 per share. The dividend payout ratio of -13.92 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -4.40, meaning Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.23
Payout Ratio-13.92
Shareholder Yield-4.40

Scores

As of September 30, 2026, Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A has an Altman Z-Score of 0.85, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.85